Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure

The incidence of pancreatic cancer has dramatically increased over the past years, but the prognosis has not improved. Between 30 and 40% of tumors are considered locally advanced, essentially due to vascular involvement. In recent years, new chemotherapy protocols with high response rates have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Sarah, Ayav, Ahmet, Lopez, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624236/
https://www.ncbi.nlm.nih.gov/pubmed/29033758
http://dx.doi.org/10.1159/000478722
_version_ 1783268215119413248
author Hahn, Sarah
Ayav, Ahmet
Lopez, Anthony
author_facet Hahn, Sarah
Ayav, Ahmet
Lopez, Anthony
author_sort Hahn, Sarah
collection PubMed
description The incidence of pancreatic cancer has dramatically increased over the past years, but the prognosis has not improved. Between 30 and 40% of tumors are considered locally advanced, essentially due to vascular involvement. In recent years, new chemotherapy protocols with high response rates have been developed. FOLFIRINOX seems to be an interesting option in this situation, but hematologic toxicity could be an obstacle to its prescription. Nab-paclitaxel and gemcitabine offer significant response rates with a reasonable safety profile. We report here a single-center experience of 2 cases with a locally advanced pancreatic cancer initially considered unresectable, progressive after first-line neoadjuvant FOLFIRINOX chemotherapy, and then treated with second-line nab-paclitaxel/gemcitabine chemotherapy.
format Online
Article
Text
id pubmed-5624236
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-56242362017-10-13 Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure Hahn, Sarah Ayav, Ahmet Lopez, Anthony Case Rep Gastroenterol Case Series The incidence of pancreatic cancer has dramatically increased over the past years, but the prognosis has not improved. Between 30 and 40% of tumors are considered locally advanced, essentially due to vascular involvement. In recent years, new chemotherapy protocols with high response rates have been developed. FOLFIRINOX seems to be an interesting option in this situation, but hematologic toxicity could be an obstacle to its prescription. Nab-paclitaxel and gemcitabine offer significant response rates with a reasonable safety profile. We report here a single-center experience of 2 cases with a locally advanced pancreatic cancer initially considered unresectable, progressive after first-line neoadjuvant FOLFIRINOX chemotherapy, and then treated with second-line nab-paclitaxel/gemcitabine chemotherapy. S. Karger AG 2017-08-04 /pmc/articles/PMC5624236/ /pubmed/29033758 http://dx.doi.org/10.1159/000478722 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Series
Hahn, Sarah
Ayav, Ahmet
Lopez, Anthony
Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title_full Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title_fullStr Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title_full_unstemmed Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title_short Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
title_sort resection of locally advanced pancreatic neoplasms after neoadjuvant chemotherapy with nab-paclitaxel and gemcitabine following folfirinox failure
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624236/
https://www.ncbi.nlm.nih.gov/pubmed/29033758
http://dx.doi.org/10.1159/000478722
work_keys_str_mv AT hahnsarah resectionoflocallyadvancedpancreaticneoplasmsafterneoadjuvantchemotherapywithnabpaclitaxelandgemcitabinefollowingfolfirinoxfailure
AT ayavahmet resectionoflocallyadvancedpancreaticneoplasmsafterneoadjuvantchemotherapywithnabpaclitaxelandgemcitabinefollowingfolfirinoxfailure
AT lopezanthony resectionoflocallyadvancedpancreaticneoplasmsafterneoadjuvantchemotherapywithnabpaclitaxelandgemcitabinefollowingfolfirinoxfailure

Ejemplares similares